Patient characteristics
high-density lipoprotein
From November 2020 to February 2022, 489 patients underwent screening, with 85 (17.4%) patients randomized and treated. Among the patients treated with pegozafermin, the distribution was as follows: placebo (Demographics and baseline characteristicsALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MRI-PDFF, magnetic resonance imaging proton density fat fraction; PGZ, pegozafermin; QW, once weekly; Q2W, once every 2 weeks; VLDL, very-low-density lipoprotein.